Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Author Correction: GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study.

Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland AV, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA.

Sci Rep. 2019 Oct 17;9(1):15168. doi: 10.1038/s41598-019-51827-0.

2.

Survival among the older adults with clinical signs of Lewy body dementia in 40 Swedish nursing homes: a 6-year follow-up study.

Zahirovic I, Torisson G, Wattmo C, Londos E.

BMJ Open. 2019 May 30;9(5):e028010. doi: 10.1136/bmjopen-2018-028010.

3.

GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study.

Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland AV, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA.

Sci Rep. 2019 May 7;9(1):7013. doi: 10.1038/s41598-019-43458-2. Erratum in: Sci Rep. 2019 Oct 17;9(1):15168.

4.

Heritability and genetic variance of dementia with Lewy bodies.

Guerreiro R, Escott-Price V, Hernandez DG, Kun-Rodrigues C, Ross OA, Orme T, Neto JL, Carmona S, Dehghani N, Eicher JD, Shepherd C, Parkkinen L, Darwent L, Heckman MG, Scholz SW, Troncoso JC, Pletnikova O, Dawson T, Rosenthal L, Ansorge O, Clarimon J, Lleo A, Morenas-Rodriguez E, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Diez-Fairen M, Aguilar M, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Graff-Radford N, Cairns NJ, Morris JC, Pickering-Brown S, Mann D, Halliday GM, Hardy J, Trojanowski JQ, Dickson DW, Singleton A; International Parkinson's Disease Genomics Consortium, Stone DJ, Bras J.

Neurobiol Dis. 2019 Jul;127:492-501. doi: 10.1016/j.nbd.2019.04.004. Epub 2019 Apr 3.

PMID:
30953760
5.

Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?

Londos E, Hansson O, Rosén I, Englund E.

BMJ Case Rep. 2019 Mar 9;12(3). pii: e228177. doi: 10.1136/bcr-2018-228177.

PMID:
30852516
6.

Living with dementia with Lewy bodies: an interpretative phenomenological analysis.

Larsson V, Holmbom-Larsen A, Torisson G, Strandberg EL, Londos E.

BMJ Open. 2019 Jan 29;9(1):e024983. doi: 10.1136/bmjopen-2018-024983.

7.

Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline.

Håkansson C, Torisson G, Londos E, Hansson O, van Westen D.

Neuroradiology. 2019 Apr;61(4):397-404. doi: 10.1007/s00234-019-02156-6. Epub 2019 Jan 17.

8.

A comprehensive screening of copy number variability in dementia with Lewy bodies.

Kun-Rodrigues C, Orme T, Carmona S, Hernandez DG, Ross OA, Eicher JD, Shepherd C, Parkkinen L, Darwent L, Heckman MG, Scholz SW, Troncoso JC, Pletnikova O, Dawson T, Rosenthal L, Ansorge O, Clarimon J, Lleo A, Morenas-Rodriguez E, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Diez-Fairen M, Aguilar M, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Pickering-Brown S, Mann D, Halliday GM, Hardy J, Trojanowski JQ, Dickson DW, Singleton A, Stone DJ, Guerreiro R, Bras J.

Neurobiol Aging. 2019 Mar;75:223.e1-223.e10. doi: 10.1016/j.neurobiolaging.2018.10.019. Epub 2018 Oct 24.

9.

Relative survival in patients with dementia with Lewy bodies and Parkinson's disease dementia.

Larsson V, Torisson G, Londos E.

PLoS One. 2018 Aug 10;13(8):e0202044. doi: 10.1371/journal.pone.0202044. eCollection 2018.

10.

Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement.

Wattmo C, Londos E, Minthon L.

Curr Alzheimer Res. 2018;15(10):905-916. doi: 10.2174/1567205015666180507105326.

11.

Author's Response to the Letter to the Editor Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives.

Londos E.

Neurol Ther. 2018 Jun;7(1):165-167. doi: 10.1007/s40120-018-0099-7. Epub 2018 Apr 27. No abstract available.

12.

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.

Sci Rep. 2018 Mar 16;8(1):4717. doi: 10.1038/s41598-018-23041-x.

13.
14.

Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study.

Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, Shepherd CE, Parkkinen L, Darwent L, Heckman MG, Scholz SW, Troncoso JC, Pletnikova O, Ansorge O, Clarimon J, Lleo A, Morenas-Rodriguez E, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Diez-Fairen M, Aguilar M, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Pickering-Brown S, Mann D, Halliday GM, Hardy J, Trojanowski JQ, Dickson DW, Singleton A, Stone DJ, Bras J.

Lancet Neurol. 2018 Jan;17(1):64-74. doi: 10.1016/S1474-4422(17)30400-3. Epub 2017 Dec 16.

15.

Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives.

Londos E.

Neurol Ther. 2018 Jun;7(1):13-22. doi: 10.1007/s40120-017-0090-8. Epub 2017 Dec 19.

16.

Effects of carbonated liquid on swallowing dysfunction in dementia with Lewy bodies and Parkinson's disease dementia.

Larsson V, Torisson G, Bülow M, Londos E.

Clin Interv Aging. 2017 Aug 8;12:1215-1222. doi: 10.2147/CIA.S140389. eCollection 2017.

17.

Importance and added value of functional impairment to predict mortality: a cohort study in Swedish medical inpatients.

Torisson G, Stavenow L, Minthon L, Londos E.

BMJ Open. 2017 May 30;7(5):e014464. doi: 10.1136/bmjopen-2016-014464.

18.

Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort.

Kramberger MG, Auestad B, Garcia-Ptacek S, Abdelnour C, Olmo JG, Walker Z, Lemstra AW, Londos E, Blanc F, Bonanni L, McKeith I, Winblad B, de Jong FJ, Nobili F, Stefanova E, Petrova M, Falup-Pecurariu C, Rektorova I, Bostantjopoulou S, Biundo R, Weintraub D, Aarsland D; E-DLB.

J Alzheimers Dis. 2017;57(3):787-795. doi: 10.3233/JAD-161109.

19.

Response to the Letter From Abid Iraqi, MD, CMD and Terry Hughes, RN, CS.

Zahirovic I, Wattmo C, Torisson G, Minthon L, Londos EY.

J Am Med Dir Assoc. 2017 Jan;18(1):84. doi: 10.1016/j.jamda.2016.10.017. No abstract available.

PMID:
28012504
20.

Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies.

Kun-Rodrigues C, Ross OA, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Ansorge O, Clark LN, Honig LS, Marder K, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, Holstege H, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Trojanowski JQ, Serrano GE, Beach TG, Clarimon J, Lleó A, Morenas-Rodríguez E, Lesage S, Galasko D, Masliah E, Santana I, Diez M, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Stone DJ, Pickering-Brown S, Mann D, Dickson DW, Halliday GM, Singleton A, Guerreiro R, Bras J.

Neurobiol Aging. 2017 Jan;49:214.e13-214.e15. doi: 10.1016/j.neurobiolaging.2016.08.023. Epub 2016 Sep 2.

22.

Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW; European DLB consortium.

J Alzheimers Dis. 2016 Aug 18;54(1):287-95. doi: 10.3233/JAD-160322.

23.

Reliability, validity and clinical correlates of the Quality of Life in Alzheimer's disease (QoL-AD) scale in medical inpatients.

Torisson G, Stavenow L, Minthon L, Londos E.

Health Qual Life Outcomes. 2016 Jun 14;14:90. doi: 10.1186/s12955-016-0493-8.

24.

Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.

Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, Zetterberg H, Mollenhauer B, Boada M, Aarsland D; European DLB Consortium.

Mov Disord. 2016 Aug;31(8):1203-8. doi: 10.1002/mds.26668. Epub 2016 Jun 14. Erratum in: Mov Disord. 2019 Apr;34(4):593.

PMID:
27296778
25.

Prevalence of Dementia With Lewy Body Symptoms: A Cross-Sectional Study in 40 Swedish Nursing Homes.

Zahirovic I, Wattmo C, Torisson G, Minthon L, Londos E.

J Am Med Dir Assoc. 2016 Aug 1;17(8):706-11. doi: 10.1016/j.jamda.2016.03.017. Epub 2016 May 7.

26.

A Diagnostic Model for Dementia in Clinical Practice-Case Methodology Assisting Dementia Diagnosis.

Londos E.

Diagnostics (Basel). 2015 Apr 2;5(2):113-8. doi: 10.3390/diagnostics5020113.

27.

Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism.

Lindqvist D, Prokopenko I, Londos E, Middleton L, Hansson O.

J Parkinsons Dis. 2016;6(1):99-108. doi: 10.3233/JPD-150693.

28.

Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases.

Guerreiro R, Escott-Price V, Darwent L, Parkkinen L, Ansorge O, Hernandez DG, Nalls MA, Clark L, Honig L, Marder K, van der Flier W, Holstege H, Louwersheimer E, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns NJ, Halliday GM, Mann D, Pickering-Brown S, Powell J, Lunnon K, Lupton MK; International Parkinson's Disease Genomics Consortium (IPDGC), Dickson D, Hardy J, Singleton A, Bras J.

Neurobiol Aging. 2016 Feb;38:214.e7-214.e10. doi: 10.1016/j.neurobiolaging.2015.10.028. Epub 2015 Nov 2.

29.

Increased CSF biomarkers of angiogenesis in Parkinson disease.

Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, Cenci MA, Hansson O.

Neurology. 2015 Nov 24;85(21):1834-42. doi: 10.1212/WNL.0000000000002151. Epub 2015 Oct 28.

30.

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients.

Wennström M, Hall S, Nägga K, Londos E, Minthon L, Hansson O.

Alzheimers Res Ther. 2015 Oct 5;7(1):63. doi: 10.1186/s13195-015-0145-y.

31.

Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.

Wattmo C, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2015;40(5-6):297-310. doi: 10.1159/000437050. Epub 2015 Sep 4.

32.

Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients.

Torisson G, van Westen D, Stavenow L, Minthon L, Londos E.

BMC Geriatr. 2015 Jun 16;15:65. doi: 10.1186/s12877-015-0066-4.

33.

Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.

Wattmo C, Londos E, Minthon L.

Clin Interv Aging. 2014 Nov 14;9:1951-62. doi: 10.2147/CIA.S71709. eCollection 2014.

34.

Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.

Wattmo C, Londos E, Minthon L.

BMC Neurol. 2014 Sep 10;14:173. doi: 10.1186/s12883-014-0173-4.

35.

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study.

Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E.

BMJ Open. 2014 Jul 3;4(7):e005158. doi: 10.1136/bmjopen-2014-005158.

36.

Risk factors that affect life expectancy in Alzheimer's disease: a 15-year follow-up.

Wattmo C, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2014;38(5-6):286-99. doi: 10.1159/000362926. Epub 2014 Jul 3.

37.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.

Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM.

Alzheimers Res Ther. 2014 May 7;6(3):25. doi: 10.1186/alzrt255. eCollection 2014.

38.

Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.

Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, Marder K, Van Der Flier WM, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns N, Halliday GM, Mann D, Pickering-Brown S, Dickson DW, Singleton A, Hardy J.

Hum Mol Genet. 2014 Dec 1;23(23):6139-46. doi: 10.1093/hmg/ddu334. Epub 2014 Jun 27.

39.

Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.

Wennström M, Nielsen HM, Orhan F, Londos E, Minthon L, Erhardt S.

Int J Tryptophan Res. 2014 Apr 28;7:1-7. doi: 10.4137/IJTR.S13958. eCollection 2014.

40.

Lack of orthostatic symptoms in dementia patients with orthostatic hypotension.

Bengtsson-Lindberg M, Larsson V, Minthon L, Wattmo C, Londos E.

Clin Auton Res. 2015 Apr;25(2):87-94. doi: 10.1007/s10286-014-0244-z. Epub 2014 Apr 18.

PMID:
24743866
41.

Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.

Wesnes KA, Aarsland D, Ballard C, Londos E.

Int J Geriatr Psychiatry. 2015 Jan;30(1):46-54. doi: 10.1002/gps.4109. Epub 2014 Apr 16.

PMID:
24737460
42.

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.

Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennström M.

J Alzheimers Dis. 2014;40(2):343-50. doi: 10.3233/JAD-132246.

PMID:
24448788
43.

Multidisciplinary intervention reducing readmissions in medical inpatients: a prospective, non-randomized study.

Torisson G, Minthon L, Stavenow L, Londos E.

Clin Interv Aging. 2013;8:1295-304. doi: 10.2147/CIA.S49133. Epub 2013 Sep 26.

44.

Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination.

Londos E, Hanxsson O, Alm Hirsch I, Janneskog A, Bülow M, Palmqvist S.

BMC Neurol. 2013 Oct 7;13:140. doi: 10.1186/1471-2377-13-140.

45.

Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.

Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K, Hansson O, Ohrfelt A.

Dement Geriatr Cogn Disord. 2013;36(1-2):99-110. doi: 10.1159/000353442. Epub 2013 Jul 9.

PMID:
23860354
46.

A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.

Wattmo C, Paulsson E, Minthon L, Londos E.

Clin Interv Aging. 2013;8:329-39. doi: 10.2147/CIA.S40087. Epub 2013 Mar 20.

47.

Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias.

Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E.

Am J Geriatr Psychiatry. 2014 Jun;22(6):580-6. doi: 10.1016/j.jagp.2012.11.001. Epub 2013 Apr 9.

PMID:
23582751
48.

A longitudinal study of physical function in patients with early-onset dementia.

Tangen GG, Londos E, Olsson J, Minthon L, Mengshoel AM.

Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):622-31. doi: 10.1159/000345782. Epub 2012 Dec 13.

49.

No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias.

Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E.

Neurosci Lett. 2012 Nov 30;531(1):1-4. doi: 10.1016/j.neulet.2012.09.062. Epub 2012 Oct 13. Erratum in: Neurosci Lett. 2014 Sep 19;580:178.

PMID:
23069674
50.

The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia.

Stubendorff K, Aarsland D, Minthon L, Londos E.

PLoS One. 2012;7(10):e45451. doi: 10.1371/journal.pone.0045451. Epub 2012 Oct 1.

Supplemental Content

Loading ...
Support Center